Sarcoidosis following alemtuzumab treatment for multiple sclerosis

被引：27

作者：

Willis, Mark D. ^{[1
,2
,3
]}

Hope-Gill, Ben ^{[4
]}

Flood-Page, Patrick ^{[5
]}

Joseph, Fady ^{[6
]}

Needham, Ed ^{[7
]}

Jones, Joanne ^{[7
]}

Coles, Alasdair ^{[7
]}

Robertson, Neil P. ^{[1
,2
,3
]}

机构：

[1] Cardiff Univ, Inst Psychol Med & Clin Neurosci, Heath Pk, Cardiff CF14 4XN, S Glam, Wales

[2] Univ Hosp Wales, Heath Pk, Cardiff CF14 4XN, S Glam, Wales

[3] Univ Hosp Wales, Dept Neurol, Cardiff, S Glam, Wales

[4] Univ Hosp Llandough, Dept Resp Med, Llandough, Wales

[5] Royal Gwent Hosp, Dept Resp Med, Newport, Gwent, Wales

[6] Royal Gwent Hosp, Dept Neurol, Newport, Gwent, Wales

[7] Addenbrookes Hosp, Dept Neurol, Cambridge, England

来源：

MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷 / 13期

关键词：

Multiple sclerosis; alemtuzumab; IMMUNE RECONSTITUTION;

D O I：

10.1177/1352458518790391

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Despite proven efficacy of alemtuzumab in multiple sclerosis (MS), approximately 50% of individuals will develop a new autoimmune disease following treatment. To date, these have largely been antibody mediated and organ specific (primarily affecting the thyroid gland). In a retrospective case series of 187 patients from two UK specialist centres (Cardiff and Cambridge) followed up for a median of 10 years, we report three (1.6%) cases of sarcoidosis following alemtuzumab treatment of MS. This report increases the spectrum of auto-inflammatory disease following alemtuzumab and should be considered by clinicians when using this therapeutic agent for MS.

引用

页码：1779 / 1782

页数：4

共 8 条

[1] Alemtuzumab Treatment of Multiple Sclerosis [J].

Coles, Alasdair F. .

SEMINARS IN NEUROLOGY, 2013, 33 (01) :66-73

[2] Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO [J].

Gelfand, Jeffrey M. ;

Cotter, Jennifer ;

Klingman, Jeffrey ;

Huang, Eric J. ;

Cree, Bruce A. C. .

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2014, 1 (03)

[3] Immune reconstitution inflammatory syndrome associated with pulmonary sarcoidosis in an HIV-infected patient: an immunohistochemical study [J].

Peixoto de Miranda, Erique Jose ;

Munhoz Leite, Olavo Henrique ;

Seixas Duarte, Maria Irma .

BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2011, 15 (06) :601-606

[4] Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab [J].

Saarela, Mika ;

Senthil, Keerthi ;

Jones, Joanne ;

Tienari, Pentti J. ;

Soilu-Hanninen, Merja ;

Airas, Laura ;

Coles, Alasdair ;

Saarinen, Jukka T. .

NEUROLOGY, 2018, 90 (18) :849-851

[5] The development of sarcoidosis with the use of alemtuzumab - clues to T-cell immune reconstitution [J].

Thachil, Jecko ;

Jadhav, Vittal ;

Gautam, Manish ;

Mckew, Steve ;

Arumainathan, Arvind ;

Collins, Daniel ;

Smyth, Colin ;

Harper, Janice ;

Pettitt, Andrew .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (04) :559-560

[6] Sarcoidosis [J].

Valeyre, Dominique ;

Prasse, Antje ;

Nunes, Hilario ;

Uzunhan, Yurdagul ;

Brillet, Pierre-Yves ;

Mueller-Quernheim, Joachim .

LANCET, 2014, 383 (9923) :1155-1167

[7] Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort [J].

Willis, M. D. ;

Harding, K. E. ;

Pickersgill, T. P. ;

Wardle, M. ;

Pearson, O. R. ;

Scolding, N. J. ;

Smee, J. ;

Robertson, N. P. .

MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (09) :1215-1223

[8] Alemtuzumab for Multiple Sclerosis [J].

Willis, Mark D. ;

Robertson, Neil P. .

CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2016, 16 (09)

← 1 →